Agomelatine, a novel therapeutic option for the management of irritable bowel syndrome.
Qin Xiang NgYu Sen Alex SohDonovan Yutong LimWee-Song YeoPublished in: Journal of clinical pharmacy and therapeutics (2018)
Numerous comorbidities are associated with IBS, including chronic pain syndromes and psychiatric disorders. Coupled with its antidepressant actions, agomelatine could serve as an effective adjunct therapeutic. Agomelatine should be considered in our therapeutic armamentarium for IBS management.